Peinoit Alexandre, Muzellec Léa, Neveu Estelle, Marchand Tony, Edeline Julien, Ricordel Charles, Choderlos De Laclos Xavier
Service d'oncologie médicale, centre Eugène-Marquis, avenue de la Bataille Flandres-Dunkerque, 35042 Rennes, France.
Service d'oncologie médicale, centre hospitalier de Cornouaille-Quimper, 14, avenue Yves-Thépot, BP 1757, 29107 Quimper cedex, France.
Bull Cancer. 2024 Sep;111(9):843-860. doi: 10.1016/j.bulcan.2024.04.011. Epub 2024 Jun 5.
Pulmonary pneumocystis causes interstitial lung disease, particularly in patients with solid cancers. The aim of this study is to clarify its incidence, which remains poorly understood, and to identify patients at risk and prognostic factors.
Data on patients with solid tumors and pulmonary pneumocystis were retrospectively collected from January 1, 2014 to December 31, 2019 in two hospitals in Rennes. Incidence was estimated via the Poisson model. Survival data were estimated using Kaplan-Meier method and Log-rank test. A multivariate Cox model was performed to identify risk factors for death.
The incidences of pulmonary pneumocystis in metastatic cancer patients receiving parenteral systemic therapy are 198 and 349 cases per 100,000 patients per year in these two centers, respectively. Most patients were being treated with corticosteroids and chemotherapy at the time of pulmonary pneumocystis. The mortality rate for patients with pulmonary pneumocystis is 38%. Median overall survival was 2,7 months. Risk factors for death are corticotherapy greater than 20mg, prednisone equivalent, daily and chemotherapy.
Pulmonary pneumocystis pneumonia is rare but not exceptional and has a poor prognosis in solid oncology. It frequently occurs in patients treated with long-term corticosteroids. Oncologists need to be better informed to discuss prophylaxis whenever corticosteroids are prescribed for several weeks.
